Weekly Digest - April 2025
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - April 2025
31 Mar 2025: SPARC announces submission of IND application for SBO-154 to USFDA
- SPARC submitted an Investigational New Drug (IND) application to the US FDA on March 31, 2025, for SBO-154, marking its entry into a global Phase 1 clinical trial for advanced solid tumors
- Preclinical IND-enabling studies for SBO-154 have shown favorable results, supporting progression into Phase 1 dose-escalation and expansion trials
- SBO-154 is SPARC’s first antibody-drug conjugate (ADC), targeting the SEA domain of the MUC1 protein, a marker commonly overexpressed in various solid tumors
- SPARC licensed the anti-MUC1 antibody component from Biomodifying, a startup from the University of Tel Aviv, for the development of SBO-154
